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BACKGROUND—To evaluate the factors associated with positive bone scans after biochemical 
recurrence (BCR) following radical prostatectomy in both hormone-naive subjects and subjects 
after androgen-deprivation therapy (ADT).
METHODS—Retrospective analysis of 380 bone scans of 301 hormone-naive subjects and 214 
bone scans of 137 subjects after ADT following BCR from the Shared Equal Access Regional 
Cancer Hospital database. Generalized estimating equations and local regression plots were used 
to evaluate bone scan positivity by patients’ demographics, pathological features, PSA levels and 
kinetics.
RESULTS—Among hormone-naive subjects and subjects on ADT, bone scan positivity was seen 
in 24 (6%) and 65 (30%) subjects, respectively. In hormone-naive subjects, the higher prescan 
PSA, higher PSA velocity (PSAV) and shorter PSA doubling time (PSADT) were significantly 
associated with positive scans (P =0.008, P<0.001 and P<0.001, respectively). In subjects after 
ADT, the prescan PSA, PSAV and PSADT were significantly associated with positive scans (P 
=0.011, P<0.001 and P =0.002, respectively). Regression plots showed increased scan positivity 
with increasing PSA levels and shortening PSADT (all P<0.001) for both hormone-naive subjects 
and subjects after ADT. For a given PSA level and PSADT, subjects on ADT had higher bone 
scan positivity.
CONCLUSIONS—In both hormone-naive subjects and subjects after ADT, more aggressive and 
advanced disease identified by higher PSA levels, higher PSAV and shorter PSADT were 
associated with higher bone scan positivity. For the same PSA level and PSADT, subjects after 
ADT had higher bone scan positivity than hormone-naive subjects. Therefore, PSA levels and 
kinetics may be used as selection criteria for bone scan in these patients.
Keywords
disease-free survival; metastasis; mortality; prostatectomy; PSA
INTRODUCTION
Bone scans are routinely used to detect metastasis in patients with prostate cancer; however, 
most scans are negative.1 Multiple studies in untreated subjects with prostate cancer suggest 
that higher PSA levels, higher Gleason scores and more advanced clinical stages are 
associated with higher risk of a positive bone scan.2-12 Patients after biochemical recurrence 
(BCR) following radical prostatectomy are at a higher risk of disease progression and the 
development of bone metastasis.13 However, presently it is unclear as to when the screening 
for bone metastasis should start, how frequent bone scans should be performed and whether 
the scans should be done at regular time intervals or triggered by changes in clinical or 
biochemical variables. To answer these important questions, one needs to first identify the 
factors associated with the development of metastasis and positive bone scans. Previously, 
Gleason score, clinical stage and PSA kinetics, such as PSA velocity (PSAV) and PSA 
doubling time (PSADT), have all been correlated with the risk that a given scan will show 
bone metastasis among hormone-naive men.14-17 Similarly, in men with castration-resistant 
nonmetastatic prostate cancer, higher PSA levels and adverse kinetics were independently 
associated with faster progression to metastatic disease and death.18,19 These findings 
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suggest that the above variables could be used to select subjects for bone scan, potentially 
minimizing the number of negative and perhaps unnecessary scans. However, there are 
limited tools to stratify patients according to their risk of positive bone scan for metastasis. 
Therefore, the primary objective of the present study is to determine the factors associated 
with positive bone scans after BCR following radical prostatectomy in both hormone-naive 
men and those who had received or were receiving androgen deprivation therapy (ADT) 
(henceforth ‘after ADT’) from the Shared Equal Access Regional Cancer Hospital 
(SEARCH) database. The secondary objective of the study is to use PSA levels and PSADT 
to stratify bone scans according to the risk of positivity.
MATERIALS AND METHODS
Study population
After obtaining institutional review board approval from each institution, data from prostate 
cancer patients with BCR following radical prostatectomy undergoing bone scan for 
suspicion of metastatic disease between 1995 and 2012 at six Veteran Affairs Medical 
Centers (West Los Angeles, Palo Alto and San Diego, CA; Augusta, GA; Durham and 
Asheville, NC) were included in the study database.20 The database included information on 
the patients’ age at the time of bone scan, race, height, weight, preoperative PSA levels, 
surgical specimen pathology (specimen weight, tumor grade, stage and surgical margin 
status), follow-up PSA, bone scans and secondary treatments after surgery. Patients treated 
with preoperative ADT or radiotherapy were excluded from the study. Bone scans following 
a positive bone scan were excluded. A total of 1 303 bone scans (from 665 subjects) after 
BCR (defined as a single PSA above 0.2 ng ml−1, 2 PSA at 0.2 ng ml−1 or secondary 
treatment for an elevated PSA level) following radical prostatectomy were identified.21 Of 
these, 97 (7%) scans were done after a positive scan and were excluded from the study. A 
total of 694 (58%) scans had complete data including PSA levels and PSA kinetics at the 
time of the scan. Of these, 100 scans (8%) with negative PSAV were excluded given that 
these likely had PSAV determined during the start of ADT when PSA level was declining. 
Such PSA kinetics do not reflect the long-term PSA trends, they only demonstrate the acute 
effect of ADT on PSA levels. This resulted in a final study sample of 594 (49%) bone scans 
(from 401 subjects). Of these, 380 (64%) bone scans were done among 301 men who had 
not received ADT and 214 (36%) scans were done in 137 subjects after ADT. Bone scans 
done within 30 days after the start of ADT were considered before ADT. Supplementary 
Figures S1 and S2 show the number of scans per patient. Secondary treatments for 
recurrence were at the discretion of the patient and the treating physician. The number and 
interval of bone scans were also at the discretion of the patient and the treating physician. 
Bone scans were read by nuclear medicine radiologists. Radiologists were not blinded to 
patients’ demographics, laboratory, radiologic or pathologic results. Bone scan reports were 
coded as positive or negative based on the radiology report (equivocal scans were 
considered negative unless confirmed positive by a secondary imaging modality).
Statistical analysis
PSADT was calculated using the natural log of two (0.693) divided by the slope of the linear 
regression of the natural log of PSA levels over time (in months). Subjects with calculated 
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PSADT >120 were assigned 120 months for the ease of analysis. PSAV was calculated as 
the slope of the linear regression of PSA levels over time in years. Subjects were required to 
have at least two values separated by at least 3 months to have PSA kinetics calculated. All 
available PSA levels before the bone scan and before ADT but after BCR (that is, >0.2 ng 
ml−1) were used to calculate preADT PSA kinetics. All available PSA levels before bone 
scan but after ADT were used to calculate postADT PSA kinetics. Subjects with three or 
more PSA values over the 3 months or more had PSA kinetics calculated. Statistical analysis 
was done by stratifying bone scans based on ADT status, that is, whether they were done in 
hormone-naive subjects or in subjects after ADT. Given the repeated-measures nature of our 
data, generalized estimating equations were used to compare patients’ demographics, 
pathological features, PSA levels and kinetics between negative and positive scans, grouping 
by patient (primary objective). PSA levels were then arbitrarily broken down into four 
groups: 0.0–4.9, 5.0–9.9, 10.0–19.9 and ≥20.0 ng ml−1. Similarly, PSADT was divided into 
three groups: ≥9, 3–8.9 and <3 months (based on previous studies correlating these values 
with mortality).22 Bar plots were used to demonstrate the relative prevalence of positive 
bone scans by PSA and PSADT groups stratified by ADT status and linear trends were 
evaluated with generalized estimating equations. We also used local regression (LOESS) 
plots to graphically represent the relationship between bone scan positivity and PSA level 
and PSADT as continuous variables stratified by ADT status. Finally, a table of point 
estimates and 95% confidence intervals for probability of bone scan positivity by PSA and 
PSADT groups stratified by ADT status were estimated from the generalized estimation 
equations (secondary objective). All statistical analyses were two-tailed and performed using 
Stata 11.2 (StataCorp, College Station, TX, USA). A P<0.05 was considered statistically 
significant.
RESULTS
Of the 308 bone scans done among hormone-naive subjects, 24 (6%) scans were positive 
and 356 (94%) were negative for metastasis (Table 1). The median time from surgery to 
recurrence was 5 years. A higher pathological Gleason score was observed among positive 
scans: 50% of the positive scans were done in subjects with Gleason scores of 4 + 3 or 8–10 
and only 34% of the negative scans were done in subjects with high-grade Gleason scores. 
This difference, however, was not statistically significant. Similarly, the prevalence of 
positive surgical margins, extracapsular extension and seminal vesicle invasion were all 
higher among positive bone scans but the differences were not statistically significant. The 
median PSAV values among subjects with positive scans (8.8 ng ml−1 per year) was 
statistically significantly higher than those with negative scans (0.6 ng ml−1 per year, 
P<0.001). The median prescan PSA values were significantly higher for positive bone scans 
(2.9 ng ml−1) compared with negative bone scans (1.1 ng ml−1, P =0.008). The median 
prescan PSADT of subjects with positive bone scans was significantly shorter than those 
with negative scans (4.7 versus 13.0 months, respectively, P<0.001).
Of the 214 bone scans done among subjects after ADT, 65 (30%) scans were positive and 
149 (70%) were negative for metastasis (Table 2). The median time from surgery to 
recurrence and that from surgery to ADT were 6.4 and 11.3 years, respectively. Similar to 
bone scans done among hormone-naive subjects, the median prescan PSA and PSAV values 
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were considerably higher (31.0 ng ml−1 and 13.4 ng ml−1 per year, respectively) for positive 
bone scans compared with negative bone scans (2.1 ng ml−1 and 1.7 ng ml−1 per year, 
correspondingly; all P<0.05). The median prescan PSADT for positive bone scans was 3.7 
months compared with 7.2 months for negative scans (P =0.002).
In both hormone-naive subjects and those after ADT, there was an increase in bone scan 
positivity with an increase in prescan PSA levels (all P for trend <0.001, Figure 1a). 
Similarly, among both groups there was an increase in bone scan positivity with shortening 
prescan PSADT (all P for trend <0.001, Figure 1b). Figure 2a shows the relationship 
between prescan PSA levels and bone scan positivity. For a given prescan PSA level, the 
bone scan positivity risk was considerably higher in subjects after ADT compared with 
hormone-naive subjects. For example, in the postADT setting, a PSA of 25 ng ml−1 
corresponded to nearly 40% risk of a positive scan, whereas in the hormone-naive setting, 
the PSA level needed to be >50 ng ml−1 before a 40% risk of a positive scan was achieved. 
Figure 2b shows the relationship between prescan PSADT and bone scan positivity. For a 
given PSADT, the bone scan positivity was likewise noticeably higher among subjects after 
ADT compared with hormone-naive subjects.
Given prescan PSA levels and PSA kinetics were the two strongest predictors of bone scan 
positivity, we developed a table that estimates bone scan positivity by prescan PSA levels 
and prescan PSADT stratified by ADT status (Table 3). For example, among bone scans 
done in hormone-naive subjects with PSADT ≥9 months, the estimated bone scan positivity 
was 5% or less compared with 10% or greater for those with PSADT <9 months. In scans 
done among subjects after ADT, for the same PSA level and PSADT, the scan positivity was 
higher compared with scans done in hormone-naive subjects with no group (even PSA <5ng 
ml−1 and PSADT >9 months) having an estimated bone scan positivity risk <10%.
DISCUSSION
With the advances in chemo- and immunotherapies for metastatic prostate cancer in recent 
years, early detection of metastasis has become more and more important. However, it is not 
clear when and how patients should be screened for metastasis. Bone scans are routinely 
used to detect metastasis in patients with prostate cancer; however, a significant number of 
these scans are negative. To better select patients for bone scans, we evaluated the predictors 
of positive bone scans. We found that the factors associated with more aggressive and 
advanced disease such as higher PSA levels, higher PSAV and shorter PSADT were 
associated with positive bone scans in both hormone-naive subjects and those after ADT. In 
other words, in both groups there was a statistically significant increase in bone scan 
positivity with an increase in prescan PSA levels and shortening PSADT. Importantly, for 
the same prescan PSA level and PSADT, the bone scan positivity was much higher among 
subjects after ADT. These results suggest that more aggressive and/or advanced diseases are 
associated with higher risk of a positive bone scan. Furthermore, they suggest that the 
factors associated with aggressive and advanced disease such as high PSA levels and short 
PSADT may be used to stratify patients based on risk of a positive bone scan. Indeed, we 
created a table combining PSA levels and PSADT to predict the risk of a positive bone scan 
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that may help clinicians estimate the risk of a positive bone scan to help guide imaging for 
men with BCR after surgery.
Only a few studies evaluated the use of PSA levels and PSA kinetics to predict metastatic 
disease in patients with recurrent disease after primary treatment for prostate cancer (radical 
prostatectomy and/or radiotherapy). Slovin et al14 found baseline PSA levels and PSADT 
were independently predictive of metastatic progression. However, in their study, they did 
not evaluate different PSA and PSADT cut points. Also, they did not include patients 
receiving ADT. Similarly, Okotie et al,15 studying hormone-naive patients after BCR 
following radical prostatectomy, found the risk of metastasis to have increased with PSADT 
shorter than 6 months (especially those with PSA levels >10 ng ml−1). Likewise, Dotan et 
al,16 also studying hormone-naive patients, found PSA levels and kinetics to be associated 
with the risk of a positive bone scan. They used pathological and biochemical variables to 
create a nomogram to predict bone scan positivity. In our study of patients after BCR 
following radical prostatectomy, we also observed an association between PSA levels and 
PSA kinetics with bone metastasis. Furthermore, we evaluated the prevalence of positive 
bone scans across multiple PSA and PSA-kinetic groups. Our results suggest that, for 
hormone-naive subjects, screening should start once PSADT is shorter than 9 months, given 
the risk of a positive bone scan in subjects with PSADT ≥9 months is 2% or less. Even 
among men with high PSA values, the estimated risk of a positive bone scan in hormone-
naive men with a long PSADT was very low. For subjects after ADT, we were unable to 
identify a subgroup where the risk of a positive scan was that low. Even the lowest risk 
groups (that is, low PSA levels and long PSADTs) had a risk of a positive scan of 10% or 
greater. This suggests that bone scan for patients after ADT should begin early—even before 
the PSA level reaches 5 ng ml−1 regardless of PSADT. Assuming the initial bone scan is 
negative, PSA levels and PSADT can be used to estimate the risk of a positive bone scan in 
these patients and help guide the timing of subsequent imaging.
The main limitation of the present study is its retrospective nature. Consequently, we were 
not able to decide when and how bone scans were performed. It is plausible that patients 
with more advanced and aggressive disease at baseline had more and earlier bone scans in 
comparison to those with less advanced and aggressive disease for whom the bone scan may 
have been deferred to a later point of time. If this hypothesis is true, some patients with 
worse disease were more likely to be diagnosed with metastasis, whereas a number of 
patients with more favorable disease may have been excluded from the study, given they 
have never had a single bone scan. Similarly, we had no control over when and how patients 
were treated with ADT. Moreover, nearly 40% of our sample had missing PSA kinetics and 
were excluded from the study. In addition, PSA measurements were not systematic and were 
at the discretion of the treating physician, which also adds noise and unwanted variability to 
the study. Also, repeated measures were present in our data (that is a single patient had more 
than one bone scan), which increase the complexity of our statistical analysis. In addition, 
the small number of events—especially in the hormone-naive population, resulted in large 
confidence intervals in our ability to estimate bone scan positivity as a function of PSA and 
PSADT. Finally, although bone scans are very sensitive to detect metastasis, false positive 
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and negative do occur, but we were unable to identify them given the confirmatory imaging 
was not available for all patients in our sample.23
In conclusion, among prostate cancer patients with BCR following radical prostatectomy, 
for a given PSA level and PSADT, subjects after ADT had a higher risk of bone scan 
positivity. More aggressive and advanced disease identified by higher PSA levels, higher 
PSAV and shorter PSADT were associated with higher risk of a positive bone scan. 
Therefore, PSA level and PSA kinetics may be used as selection criteria for performing bone 
scans in both hormone-naive subjects and subjects after ADT.
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Figure 1. 
Bone scan positivity by prescan PSA (a) and PSADT (b) groups. ADT, androgen-
deprivation therapy; PSADT, PSA doubling time.
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Figure 2. 
Bone scan positivity by prescan PSA (a) and PSADT (b) levels. ADT, Androgen 
deprivation therapy; PSADT, PSA doubling time.
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Table 1
Bone scans done after BCR and before ADT
Variables Positive bone scan Negative bone scan OR (95% CI)a Pb
Bone scans, Total N (%) 24 (6) 356 (94) — —
Age (years), median (Q1, Q3) 69 (65, 77) 68 (64, 74) 1.03 (0.97–1.08) 0.352
Race, N (%) 0.628
 White 16 (67) 231 (65) ref.
 Black 6 (25) 109 (31) 0.79 (0.30–2.07)
 Other 2 (8) 16 (4) 1.81 (0.38–8.49)
Year of scan (years), median (Q1, Q3) 2004 (1998, 2008) 2004 (1999, 2007) 0.98 (0.90–1.07) 0.704
Preoperative PSA (ng ml−1), median (Q1, Q3) 11.9 (7.2, 18.2) 9.2 (5.7, 16.7) 1.00 (0.996–1.003) 0.808
Pathological Gleason score, N (%) 0.411
 2–6 3 (17) 76 (25) ref.
 3+4 6 (33) 127 (41) 1.20 (0.29–4.93)
 4+3, 8–10 9 (50) 107 (34) 2.13 (0.56–8.13)
Positive surgical margins, N (%) 11 (61) 162 (56) 1.23 (0.46–3.24) 0.681
Extracapsular extension, N (%) 11 (58) 104 (36) 2.46 (0.97–6.23) 0.057
Seminal vesicle invasion, N (%) 5 (26) 64 (20) 1.45 (0.51–4.15) 0.486
Lymph nodes, N (%) 0.932
 Positive 1 (4) 11 (3) 1.45 (0.18–11.91)
 Negative 16 (73) 257 (73) ref.
 Unknown 5 (23) 85 (24) 0.94 (0.34–2.65)
Prescan PSA (ng ml−1), median (Q1, Q3) 2.9 (0.6, 12.3) 1.1 (0.4, 3.4) 1.03 (1.01–1.05) 0.008
Prescan PSADT (months), median (Q1, Q3) 4.7 (3.1, 7.8) 13.0 (7.9, 23.9) 0.25 (0.14–0.47)c <0.001
Prescan PSAV (ng ml−1 per year), median (Q1, Q3) 8.8 (1.7, 42.0) 0.6 (0.2, 1.5) 1.06 (1.03–1.09) <0.001
Time from BCR to scan (months), median (Q1, Q3) 31.5 (21.7, 62.0) 30.1 (13.3, 59.8) 1.00 (0.99–1.01) 0.848
Abbreviations: ADT, androgen-deprivation therapy; BCR, biochemical recurrence; CI, confidence interval; OR, odds ratio; PSADT, PSA doubling 
time; PSAV, PSA velocity; Q1, 25th percentile; Q3, 75th percentile; ref., reference group.
Missing values indicate that the model did not converge.
aOdds ratios are estimated using GEE logistic regression.
b
P-values are for the significance of the covariate in predicting risk of a bone scan being positive, across all patients.
clog-transformed PSADT was used in this analysis.
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Table 2
Bone scans done after BCR and after ADT
Variables Positive bone scan Negative bone scan OR (95% CI)a Pb
Bone scans, N (%) 65 (30) 149 (70) — —
Age (years), median (Q1, Q3) 71 (65, 76) 70 (64, 77) 1.01 (0.98–1.05) 0.502
Race, N (%) 0.550
 White 47 (73) 98 (66) ref.
 Black 15 (24) 45 (30) 0.70 (0.36–1.36)
 Other 2 (3) 6 (4) 0.71 (0.14–3.63)
Year of scan (years), median (Q1, Q3) 2006 (2001, 2008) 2006 (2003, 2008) 0.94 (0.88–1.01) 0.088
Preoperative PSA (ng ml−1), median (Q1, Q3) 10.5 (6.4, 17.9) 9.4 (6.4, 15.2) 1.00 (0.9998–1.0002) 0.391
Pathological Gleason score, N (%) 0.097
 2–6 9 (15) 9 (7) ref.
 3+4 14 (23) 45 (33) 0.30 (0.10–0.90)
 4+3, 8–10 38 (62) 80 (60) 0.44 (0.16–1.18)
Positive surgical margins, N (%) 33 (57) 75 (60) 0.86 (0.46–1.60) 0.631
Extracapsular extension, N (%) 33 (58) 60 (49) 1.42 (0.76–2.66) 0.272
Seminal vesicle invasion, N (%) 29 (48) 57 (41) 1.31 (0.73–2.35) 0.361
Lymph nodes, N (%) 0.941
 Positive 6 (9) 16 (11) 0.84 (0.31–2.26)
 Negative 51 (80) 116 (78) ref.
 Unknown 7 (11) 17 (11) 0.95 (0.37–2.41)
Prescan PSA (ng ml−1), median (Q1, Q3) 31.0 (5.6, 151.3) 2.1 (0.4, 13.2) 1.002 (1.0006–1.004) 0.011
Prescan PSADT (months), median (Q1, Q3) 3.7 (2.9, 6.9) 7.2 (4.1, 13.9) 0.58 (0.41–0.82)c 0.002
Prescan PSAV (ng ml−1 per year), median (Q1, Q3) 13.4 (4.3, 48.9) 1.7 (0.44, 6.0) 1.011 (1.005–1.016) <0.001
Time from BCR to scan (months), median (Q1, Q3) 55.6 (33.8, 107.6) 71.8 (39.4, 105.5) 0.998 (0.991–1.004) 0.491
Abbreviations: ADT, androgen deprivation therapy; BCR, biochemical recurrence; CI, confidence interval; OR, odds ratio; PSADT, PSA doubling 
time; PSAV, PSA velocity; Q1, 25th percentile; Q3, 75th percentile; ref., reference group.
Missing values indicate that the model did not converge.
aOdds ratios are estimated using GEE logistic regression.
b
P-values are for the significance of the covariate in predicting risk of a bone scan being positive, across all patients.
clog-transformed PSADT was used in this analysis.
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